Cardiogenic Shock in Acute MI

Similar documents
Cardiogenic Shock. Carlos Cafri,, MD

Acute heart failure: ECMO Cardiology & Vascular Medicine 2012

Rationale for Prophylactic Support During Percutaneous Coronary Intervention

Percutaneous Mechanical Circulatory Support Devices

Percutaneous Mechanical Circulatory Support for Cardiogenic Shock. 24 th Annual San Diego Heart Failure Symposium Ryan R Reeves, MD FSCAI

Bridging With Percutaneous Devices: Tandem Heart and Impella

Cath Lab Essentials : LV Assist Devices for Hemodynamic Support (IABP, Impella, Tandem Heart, ECMO)

How to do Primary Angioplasty. - Patients with Cardiogenic Shock

AllinaHealthSystem 1

ST-Elevation Myocardial Infarction & Cardiogenic Shock. - What Should We Do?

Ted Feldman, M.D., MSCAI FACC FESC

DECLARATION OF CONFLICT OF INTEREST

Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend )

Management of Cardiogenic Shock. Dr Stephen Pettit, Consultant Cardiologist

STEMI and Cardiogenic Shock. The rules and solution. Dave Kettles St Dominics and Frere Hospitals East London ZA

Οξύ στεφανιαίο σύνδρομο και καρδιογενής καταπληξία. Επεμβατική προσέγγιση. Σωτήριος Πατσιλινάκος Κωνσταντοπούλειο Γ.Ν. Ν. Ιωνίας

Introduction to Acute Mechanical Circulatory Support

Circulatory Support: From IABP to LVAD

A case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD

Case - Advanced HF and Shock (INTERMACS 1)

MANAGEMENT OF CARDIOGENIC SHOCK

Ray Matthews MD Professor of Clinical Medicine Chief of Cardiology University of Southern California

STEMI ST Elevation Myocardial Infarction

New Horizons in Cardiogenic Shock. Timothy D. Henry, MD Director of Cardiology Cedars-Sinai Heart Institute

Management of Acute Shock and Right Ventricular Failure

CARDIOGENIC SHOCK. Antonio Pesenti. Università degli Studi di Milano Bicocca Azienda Ospedaliera San Gerardo Monza (MI)

Extra Corporeal Life Support for Acute Heart failure

TREATMENT OF HIGHER RISK PATIENTS INTRODUCTION TO PROTECTED PCI WITH IMPELLA. IMP v4

Rationale for Left Ventricular Support During Percutaneous Coronary Intervention

Acute Myocardial Infarction Complicated by Cardiogenic Shock

Antonio Colombo. Centro Cuore Columbus and S. Raffaele Scientific Institute, Milan, Italy. Miracor Symposium. Speaker: 15. Parigi: May 16-19, 2017

PHARMACOLOGICAL MANAGEMENT OF CARDIOGENIC SHOCK

Modern Left Ventricular Assist Devices (LVAD) : An Intro, Complications, and Emergencies

Out-of-hospital Cardiac Arrest. Franz R. Eberli MD, FESC, FAHA Cardiology Triemli Hospital Zurich, Switzerland

Controversies in Cardiogenic Shock. Timothy D. Henry, MD Cedars-Sinai Heart Institute

Emergency surgery in acute coronary syndrome

4. Which survey program does your facility use to get your program designated by the state?

Management of Cardiogenic shock. Prof. Christian JM Vrints

Stayin Alive: Pediatric Advanced Life Support (PALS) Updated Guidelines

Guideline compliance, utilization trends

Complications of Acute Myocardial Infarction

E-CPR National Trends & Local Plans

E-CPR National Trends & Local Plans

เอกราช อร ยะช ยพาณ ชย

Acute Coronary Syndromes

Counterpulsation. John N. Nanas, MD, PhD. Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece

Cindy Stephens, MSN, ANP Kelly Walker, MS, ACNP Peter Cohn, MD, FACC

PUMP FAILURE COMPLICATING AMI: ISCHAEMIC VSR

Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014

Who is the high risk patient?

Referral for Heart Transplantation - who and when?

Cardiogenic Shock Protocol

2010 ACLS Guidelines. Primary goals of therapy for patients

Medical Management of Acute Heart Failure

Acute Coronary Syndrome. Sonny Achtchi, DO

Rhythm Disorders 2017 TazKai LLC and NRSNG.com

IABP SHOCK II trial:

CABG Surgery following STEMI

Which mechanical assistance for cardiogenic shock?

In-hospital Care of the Post-Cardiac Arrest Patient. David A. Pearson, MD, FACEP, FAAEM Associate Program Director Department of Emergency Medicine

2/26/2013. NCDR.13 Case Scenario Presentation Cath PCI Registry. Disclosures. Objectives. Dashboard Implications of Some Major Metrics

Ventricular Assisting Devices in the Cathlab. Unrestricted

Angina Luis Tulloch, MD 03/27/2012

Sanford Chest Pain Network: Improving Rural STEMI Outcomes

Unstable: Hypotension/Shock, Fever, Altered Mental Status, Chest discomfort, Acute Heart Failure Saturation <94%, Systolic BP < 90mmHg

Appropriate Timing for Coronary Revascularization Post - MI. Manesh R. Patel, MD Assistant Professor of Medicine Duke University Medical Center

Post Cardiac Arrest Care 2015 American Heart Association Guideline Update for CPR and Emergency Cardiovascular Care

Disclosures. Extra-Corporeal Membrane Oxygenation During Cardio- Pulmonary Resuscitation ECPR April 22, 2016 ECG. Case. Case. Case Summary 4/22/2016

The Role of Mechanical Circulatory Support in Cardiogenic Shock: When to Utilize

Cardiogenic Shock and Initiatives to Reduce Mortality

Acute heart failure in a patient with lower urinary tract infection Case report of an infection-induced Reverse Takotsubo syndrome

APPENDIX F: CASE REPORT FORM

The Optimal Team for 24/7 CCU shock management

Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist. Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI

A Future for the IABP in Cardiogenic Shock? Holger Thiele Medical Clinic II (Cardiology/Angiology/Intensive Care) University of Lübeck, Germany

Low cardiac output & Mechanical Support นายแพทย อรรถภ ม ส ศ ภอรรถ ศ ลยศาสตร ห วใจและทรวงอก โรงพยาบาล ราชว ถ

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions.

8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes

Role of echocardiography in the assessment of ischemic heart disease 분당서울대학교병원윤연이

2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non ST-Elevation Myocardial Infarction

Acute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine

4/22/2016 Updated. AllinaHealthSystem. Cardiogenic Shock: Definition. No Disclosures. Cardiogenic Shock: Declining (But Still High) Case Fatality Rate

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Complications of Myocardial Infarction

Assist Devices in STEMI- Intra-aortic Balloon Pump

CENTRAL ECMO WHEN AND HOW? RANJIT JOHN, MD UNIVERSITY OF MINESOTA

Andrew Civitello MD, FACC

Medical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011

Pre Hospital and Initial Management of Acute Coronary Syndrome

Cardiogenic shock: Current management

Cardiovascular emergencies. 05/March/2014 László Rudas Szeged

Definition. Low-cardiac-output state resulting in life threatening end-organ hypoperfusion. Criteria: MAP 30 mm Hg lower than baseline)

New Jersey Cardiac Catheterization Data Registry, Version 2.0 (Please report data only for patients 16 years or older.)

DISCUSSION QUESTION - 1

Mechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know!

Echo assessment of patients with an ECMO device

I Was Too Late With Device Placement

Cardiac Arrhythmias in Acute Coronary Syndrome. Roj Rojjarekampai, MD Thammasart Hospital 26/5/59

Difficult Data Definitions and Scenario s

Objectives: This presentation will help you to:

Transcription:

Cardiogenic Shock in Acute MI Mark Sheldon, MD UNMH Interventional Cardiology

Objectives Overview Treatment Definition Shock profiles Causes Medical Mechanical Illustrative case Questions? Revascularization methods Basics of various methods of support

Pathophysiology Basics

CS Defined Low cardiac output/index < 1.8 l/min/m2 without support < 2.0-2.2 l/min/m2 with support Relative hypotension < 80-90 mmhg systolic Mean pressure < 60 mmhg Poor tissue oxygenation End organ failure

Hemodynamic Profiles Learntheheart.com

CS Epidemiology Incidence in MI decreasing since the 70 s: ~7% to <6% since the late 90 s Mortality rates decreasing: Why? Historically- 80-90% Currently- about 50% (40-70%)

Causes LV pump failure (80%) RV pump failure (5-6%) Acute mitral valve insufficiency (7%) Ventricular rupture (<2%) or VSD (4%) Concomitant aortic/mitral stenosis Others

Clinical manifestations Hypotension Hypoperfusion: Oliguria Cool extremities Altered mental status Pulmonary congestion Metabolic acidosis Elevated Lactate

Treatment-Medical Usual medical therapy Aspirin Clopidogrel/Ticagrelor/Prasugrel Heparin Avoid beta blockers Inotropes/Pressors Hypotensive: Dopamine/Norepinephrine Not hypotensive: Dobutamine

Treatment-Mechanical Revascularization SHOCK trial PPCI greatly preferred over fibrinolytics Culprit artery first Multi-vessel revascularization? PCI vs. Surgery

SHOCK Trial

Treatment-Mechanical Intra-aortic balloon pump Left ventricular assist devices Impella(percutaneous) Tandem Heart (percutaneous) LVAD (surgical) ECMO (surgical/percutaneous)

IABP Mechanics nmcheartcare.ae

IABP Arterial Waveform Ganfyd.org

ImpellaCatheter Abiomed.com

Impellapositioning medpagetoday.com

ECMO Circuit ecmosimulation.com

Treatment of Cardiogenic Shock: Recommendations-ACC/AHA CLASS I Emergency revascularization with either PCI or CABG is recommended in suitable patients with cardiogenic shock due to pump failure after STEMI irrespective of the time delay from MI onset (212,379,452). (Level of Evidence: B) In the absence of contraindications, fibrinolytic therapy should be administered to patients with STEMI and cardiogenic shock who are unsuitable candidates for either PCI or CABG (81,453,454). (Level of Evidence: B)

Treatment of Cardiogenic Shock: Recommendations-ACC/AHA CLASS IIa The use of intra-aortic balloon pump (IABP) counterpulsationcan be useful for patients with cardiogenic shock after STEMI who do not quickly stabilize with pharmacological therapy (455,456,457,458,459). (Level of Evidence: B) CLASS IIb Alternative LV assist devices for circulatory support may be considered in patients with refractory cardiogenic shock. (Level of Evidence: C)

Guideline Evolution More recent European Guidelines deemphasized IABP s and brought up the recommendations for percutaneous LVAD s (Impella)

Case

CS 1 68 yowoman with a history of HTN, HLP, active smoking, known CAD, s/p BMS of the RCA for an ACS 8 years ago. Also has a history of poor medical compliance and has not seen a physician for 5+ years. Chest discomfort then N/V >> collapsed at home VF found and shocked x 4, CPR, + 3 mg epi and 70 mg lidocaine with ROSC Intubated and brought to UNMH ED

UNMH ED Vitals: 70/40, 75, intubated Pulse was lost (PEA) and CPR resumed with more Epi given and amiodarone/shock given for pulseless VT ROSC with a blood pressure of 185/100, then down to the 90 s systolic >> dopamine begun Taken to the cathlab

UNM Cath Lab Upon arrival to the cathlab bradycardic and hypotensive again TVP placed Norepinephrine begun

Angios

After RCA stents x 2-still hypotensive requiring IABP and dopamine/norepinephrine What next? Impella? ECMO? Further Revasc?

Hospital Course Dopamine weaned off in the cathlab prior to transfer <24 hours- norepinephrine weaned off 36 hours- IABP removed and extubated Full neurologic recovery LVEF on TTE 45-50% with inferior hypokinesis Discharged on Hospital day 6

Any Further Questions Mark Sheldon Email: masheldon@salud.unm.edu Phone: 505-272-9223